Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$3.6 - $5.25 $19,764 - $28,822
5,490 New
5,490 $23,000
Q2 2022

Aug 12, 2022

SELL
$2.6 - $6.14 $7,124 - $16,823
-2,740 Closed
0 $0
Q2 2021

Aug 06, 2021

BUY
$85.37 - $114.1 $51,819 - $69,258
607 Added 28.46%
2,740 $234,000
Q1 2021

May 14, 2021

SELL
$109.73 - $153.66 $1,975 - $2,765
-18 Reduced 0.84%
2,133 $245,000
Q2 2020

Aug 05, 2020

BUY
$44.04 - $80.69 $19,377 - $35,503
440 Added 25.72%
2,151 $155,000
Q4 2019

Feb 13, 2020

BUY
$66.49 - $137.73 $6,117 - $12,671
92 Added 5.68%
1,711 $163,000
Q3 2019

Nov 14, 2019

BUY
$31.0 - $89.73 $4,185 - $12,113
135 Added 9.1%
1,619 $127,000
Q2 2019

Aug 14, 2019

BUY
$36.0 - $44.73 $11,268 - $14,000
313 Added 26.73%
1,484 $64,000
Q1 2019

May 15, 2019

BUY
$33.79 - $51.99 $16,523 - $25,423
489 Added 71.7%
1,171 $47,000
Q3 2018

Nov 13, 2018

BUY
$31.25 - $47.64 $21,312 - $32,490
682 New
682 $31,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $89.8M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Ameritas Investment Partners, Inc. Portfolio

Follow Ameritas Investment Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.